Epidermolysis Bullosa

🧠 Standard of Care & Symptoms

Epidermolysis Bullosa (EB) is a heterogeneous group of rare, inherited connective tissue disorders characterized by extreme fragility of the skin and mucous membranes. Minor mechanical trauma, friction, or heat triggers painful blisters and superficial erosions.

• Presentation: Key clinical features and subtypes.
  • *Fragile Blisters:* Fluid-filled blisters that form in response to minimal friction (e.g. from clothing, diapers, or touch).
  • *Chronic Erosions:* Open, slow-healing wounds that arise from ruptured blisters. They serve as major entry points for bacteria, leading to chronic infections.
  • *Extracutaneous Complications:* Severe subtypes present with corneal abrasions, esophageal strictures (causing dysphagia), microstomia (narrowed mouth opening), and severe anemia.
  • *Pseudosyndactyly:* In Recessive Dystrophic EB, chronic blistering and scarring of the hands and feet can cause the digits to fuse together, forming a glove-like deformity (**mitten deformities**).

🧬 Diagnostics & Genetic Pathophysiology

Diagnosis is established via skin biopsy analysis to determine the exact level of skin cleavage, followed by genetic sequencing.

• Diagnostic Markers: Key criteria.
  • Immunofluorescence Antigen Mapping (IFM): Deployed on a fresh skin biopsy to identify the absent or reduced structural protein and determine if cleavage is intraepidermal, junctional, or sub-lamina densa.
  • Transmission Electron Microscopy (TEM): Visualizes hemidesmosomes, anchoring fibrils, and individual basement membrane structures to confirm the ultrastructural defect.
  • Genetic Testing: Multi-gene panel sequencing identifies mutations in *KRT5/KRT14*, *LAMA3/LAMB3/LAMC2*, *COL17A1*, or *COL7A1* to establish the exact genetic subtype.

Pathophysiology of Dermo-Epidermal Cleavage

The severity and level of blistering in EB depend on the specific structural protein affected by genetic mutations:

• Epidermolysis Bullosa Simplex (EBS): Driven by mutations in the *KRT5* or *KRT14* genes encoding **Keratin 5** and **Keratin 14**. This leads to structural failure of the basal keratinocyte cytoskeleton, causing intraepidermal splitting within the basal cell layer.
• Junctional Epidermolysis Bullosa (JEB): Caused by mutations in genes encoding **Laminin 332** (*LAMA3, LAMB3, LAMC2*) or **Type XVII Collagen** (*COL17A1*). This disrupts the hemidesmosome-anchoring filament complex, causing clefting within the lamina lucida of the basement membrane zone.
• Dystrophic Epidermolysis Bullosa (DEB): Triggered by mutations in the *COL7A1* gene encoding **Type VII Collagen**. Type VII collagen forms the anchoring fibrils that secure the basement membrane to the underlying dermis. Loss of functional anchoring fibrils leads to sub-lamina densa cleavage and extensive scarring.

💊 Wound Management & Gene Therapies

Therapy focuses on protective wound care, preventing secondary infection, and utilizing newly approved molecular gene therapies.

Standard Wound Care Protocols

• Blister Decompression: Clean blisters should be punctured at their lowest point using a sterile needle to drain fluid, preventing lateral extension, while keeping the blister roof intact to protect the wound bed.
• Non-Adherent Dressings: Traditional adhesive bandages must never be used. Wounds are dressed using non-adherent, silicone-based layers covered by protective retention bandages.
• Nutritional Support: Crucial for DEB patients. Increased caloric and protein intake is required to compensate for chronic protein loss through wound exudate and to support wound healing.

FDA-Approved Gene Therapies

• Vyjuvek (Beremagene Geperpavec): A topical, redosable, replication-deficient herpes simplex virus type 1 (HSV-1) vector-based gene therapy. It delivers functional copies of the *COL7A1* gene directly to cells in open wounds of Dystrophic EB patients, promoting Type VII collagen expression and wound closure.
• Filsuvez (Birch Bark Extract): A topical gel containing triterpenes, approved to promote the healing of partial-thickness wounds in Junctional and Dystrophic EB.

🔬 Active Clinical Trials

Clinical trials are actively investigating gene-corrected autologous grafts, systemic gene therapies, and anti-inflammatory biologics.

🗺️ Next Steps After Diagnosis

If you or your child has recently been diagnosed with Epidermolysis Bullosa, establish these clinical care pathways:

1. Perform Subtype Genetic Confirmation: Confirm the exact genetic mutation to determine the inheritance pattern and baseline prognosis.
2. Engage an EB Specialist Center: Seek care at a designated EB clinical center to coordinate dermatology, wound care, pediatrics, and nutrition.
3. Adopt Silicone-Based Bandaging: Transition all wound care to non-adherent silicone layers and tubular retention dressings.
4. Assess for Topical Gene Therapy: Discuss with your dermatologist if you qualify for topical **Vyjuvek** treatments for chronic dystrophic EB wounds.

❓ Patient FAQ

Q: What is the risk of skin cancer in Epidermolysis Bullosa?
A: Patients with Recessive Dystrophic EB (RDEB) have a very high risk of developing aggressive **Squamous Cell Carcinoma (SCC)** in areas of chronic, non-healing wounds, often starting in early adulthood. Regular skin checks by an experienced dermatologist are critical.

Q: How do you prevent esophageal strictures in severe EB?
A: Esophageal strictures are managed by adopting a soft or pureed diet to reduce mechanical injury to the esophagus. If strictures develop, they are treated via endoscopic balloon dilatation, which must be performed with extreme care to avoid mucosal tearing.